What is HC Wainwright’s Forecast for MIST FY2028 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – HC Wainwright cut their FY2028 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $0.43 per share for the year, down from their previous estimate of $0.46. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Trading Down 2.0 %

MIST stock opened at $1.95 on Wednesday. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The stock has a market cap of $104.04 million, a price-to-earnings ratio of -2.41 and a beta of 1.83. The business’s 50-day moving average is $2.02 and its 200 day moving average is $1.81.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently bought and sold shares of MIST. Atria Investments Inc boosted its holdings in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares during the last quarter. PVG Asset Management Corp purchased a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $46,000. Jones Financial Companies Lllp lifted its stake in Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares in the last quarter. Virtu Financial LLC purchased a new position in Milestone Pharmaceuticals in the 4th quarter worth approximately $170,000. Finally, National Bank of Canada FI lifted its stake in Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after purchasing an additional 11,600 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.